Prevalence of Lipohypertrophy and Associated Risk Factors in Insulin-Treated Patients With Type 2 Diabetes Mellitus

Authors Information
Article Notes and Dates
To Cite : Al Ajlouni M, Abujbara M, Batieha A, Ajlouni K. Prevalence of Lipohypertrophy and Associated Risk Factors in Insulin-Treated Patients With Type 2 Diabetes Mellitus, Int J Endocrinol Metab. 2015 ;13(2):e20776. doi: 10.5812/ijem.20776.
Copyright: Copyright © 2015, International Journal of Endocrinology and Metabolism. .
Abstract
1. Introduction
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837-53[PubMed]
  • 2. Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, et al. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J. 2005; 52(5): 623-8[PubMed]
  • 3. Seyoum B, Abdulkadir J. Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Trop Doct. 1996; 26(4): 159-61[PubMed]
  • 4. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003; 4(10): 661-7[PubMed]
  • 5. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996; 104(2): 106-10[DOI][PubMed]
  • 6. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013; 39(5): 445-53[DOI][PubMed]
  • 7. Carr DB, Utzschneider KM, Hull r. l. , Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes Metab. 1996; 53: 2087-94
  • 8. American Diabetes A. Standards of medical care in diabetes--2011. Diabetes Care. 2011; 34 Suppl 1-61[DOI][PubMed]
  • 9. Kasha Z, Haiheydan Z, Akha O, Akbarzadeh S. Prevalence of lipodystrophy associated with recombinant insulin. Mazandaran Uni Med Sci J. 2008; 18: 9
  • 10. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003; 327(7411): 383-4[DOI][PubMed]
  • 11. Hambridge K. The management of lipohypertrophy in diabetes care. Br J Nurs. 2007; 16(9): 520-4[DOI][PubMed]
  • 12. Sea-de Ibarra L, Gallego F. Factors related to Lipohypertrophy in insulin-treated diabetic patients: role of educational intervention. Practical Diab Int. 1998; 15(1): 9–11
  • 13. Malwa G, Balami D, Deshmukh S, Groft M, Bodmer C, Patel M. Insulin-induced Lipohypertrophy, past present and future: are we lose the bottle. Endocrine. 2010; 22: 268
  • 14. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007; 77(2): 231-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

International Journal of Endocrinology and Metabolism accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check